20,650 Shares in Bristol Myers Squibb Company $BMY Bought by Miller Global Investments LLC

Miller Global Investments LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 20,650 shares of the biopharmaceutical company’s stock, valued at approximately $1,114,000. Bristol Myers Squibb makes up approximately 1.0% of Miller Global Investments LLC’s holdings, making the stock its 25th largest holding.

Several other institutional investors and hedge funds have also recently bought and sold shares of BMY. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth about $25,000. Harbor Capital Advisors Inc. increased its stake in Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the period. KERR FINANCIAL PLANNING Corp bought a new stake in Bristol Myers Squibb in the third quarter valued at about $35,000. JPL Wealth Management LLC acquired a new position in Bristol Myers Squibb in the third quarter worth about $36,000. Finally, Total Investment Management Inc. bought a new position in Bristol Myers Squibb during the second quarter worth about $38,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 2.0%

BMY opened at $58.17 on Friday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The stock has a market capitalization of $118.46 billion, a PE ratio of 16.86, a PEG ratio of 0.17 and a beta of 0.26. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The firm has a 50-day moving average price of $58.57 and a two-hundred day moving average price of $51.74.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.Bristol Myers Squibb’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BMY shares. UBS Group reaffirmed a “buy” rating and set a $70.00 price objective on shares of Bristol Myers Squibb in a report on Friday, March 6th. Morgan Stanley restated an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Guggenheim reaffirmed a “buy” rating and issued a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. HSBC upped their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday. Finally, Citigroup lifted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $61.41.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.